Grech V,* DeGiovanni JV.** Patent arterial duct occlusion with two Amplatzer Duct Occluder devices. Images Paediatr Cardiol. 2011;13(4) 6-9

*Editor-in-Chief, Images in Paediatric Cardiology and Associate Professor of Paediatrics, Mater Dei Hospital, Malta

**Consultant Paediatric Cardiologist, Birmingham Children’s Hospital, UK

MeSH

Ductus Arteriosus, Patent
Heart defects, congenital
Embolization, Therapeutic, Instrumentation
Heart Catheterization/Instrumentation

Abstract

It is accepted practice to close large patent arterial ducts (PDA) with Amplatzer duct occluder devices, with extremely low rates of residual PDA. We report a child who required device closure of PDA with two Amplatzer PDA devices on two separate occasions, despite the first device deployment being a standard placement of an appropriately sized Amplatzer device in the usual position.

Introduction

Since the first case of transcatheter closure of patent ductus arteriosus (PDA) by Porstmann in 1967,(1) device closure has become a mainstream form of intervention for this lesion with a wide variety of devices.(2)

The Amplatzer PDA occluder is a self-expanding nitinol double-disk device and consists of two disks of varying sizes with the larger disk positioned at the aortic end of the duct. Since its introduction, this device remains, to date, the device of choice for the transcatheter occlusion of large (>3mm) PDAs,(3) and the exact technique for device deployment has been previously described.(4)

We report one child who required device closure of PDA with two Amplatzer PDA devices on two separate occasions.

Patient

Our patient was born in March 2001 and a murmur was noted shortly after birth. Echocardiography eventually showed a large PDA, and followup did not reveal signs of pulmonary hypertension. An Amplatzer PDA device (8 by 6 mm) was implanted at almost 3 years of age (figure 1).
Clinical and echocardiographic signs of significant left heart volume overload persisted. Repeat cardiac catheterization showed a significant residual shunt (figures 2 and 3) and a second device (10 by 8 mm) was implanted at 4 years and 3 months of age, 1½ years after the first device was implanted (figures 4 and 5), with little residual shunting.
**Discussion**

The Amplatzer ductal occluder is a safe device and has been utilized extensively with few complications in competent hands. (5) Closure rates of >99% have been documented, (5) and follow-up has not revealed any episodes of delayed device migration, endocarditis, thromboembolism, or wire fracture/device disruption. (6) Our patient is unusual in that despite standard placement of an appropriately sized Amplatzer device in the usual position, significant residual shunting necessitated the placement of a second device.

**References**

